In cancer, FIRΔexon2 inhibits the FIR–P62 interaction as dominant negative for FIR, triggering P62 shifts to interact with RPB6 of RNAPI/II rather than P62-FIR interaction for activating rRNA and mRNA activation (Figure. Here, PUF60 is linked to cancer.